BioSpace News Archive

PreciseDx today announced the appointment of Bradley Gendell as Chief Financial Officer.

BioPhotas, Inc., the manufacturer of the award-winning Celluma SERIES of light therapy devices, announced that it is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, California.

Hyperfine, Inc., the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system, announced CE Marking for the product.

Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C. (www.hatchmedical.com) announced recently that it has been retained by EndoBar Solutions, LLC to broker a strategic transaction related to its robotic embolization system, Lamina™.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 (“the Study”) demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation in reducing blood pressure (“BP”).

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs) will be presenting at the Emerging Growth Conference on February 22, 2023.

The US Patent and Trademark Office has granted Tricol Biomedical, a global leader in innovating hemostasis and wound care solutions, a new patent (#11,564,673) for the company’s modified chitosan dressing and its through-the-scope delivery in the gastrointestinal (GI) tract to quickly control serious bleeding for up to 96 hours.

Molecular Designs, LLC, a developer and manufacturer of molecular multiplex pathogen assays, announced the successful completion of a recent ISO 13485:2016 inspection and certification of its Quality Management System.

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth quarter and year-end 2022 financial results after the close of the market on Monday, March 6, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.